Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 


US grants Pacific Edge patent for melanoma detection


US grants Pacific Edge patent for melanoma detection

4 September 2014

The United States Patent Office has granted Pacific Edge patent protection for 'Prognosis Prediction for Melanoma'. The patent covers the technology being used to develop the melanoma prognostic test that will enable clinicians to distinguish aggressive and life threatening melanomas from those that are not as aggressive.

“It is the aggressive tumours that will kill you” Pacific Edge Chief Executive Officer David Darling says.

The test applies a gene signature to a tissue sample taken from the melanoma to detect its aggressiveness allowing clinicians to prescribe the appropriate level of treatment. Specifically, the test in development identifies aggressiveness in Stage III melanomas.

Pacific Edge partnered with the Ludwig Institute of Cancer Research, the world’s largest not-for-profit cancer research organisation, to develop the technology. This successful partnership has enabled Pacific Edge to develop the prototype product for detecting aggressiveness in Stage III melanomas.

The USA is the third jurisdiction after China and New Zealand to grant patent protection for the ‘Prognosis Prediction for Melanoma’ test that is in the development stage.

The melanoma test is one of several cancer products that the Company has worked up to prototype level prior to focussing resources on the successful launch and further development of its Cxbladder technology for detecting and managing bladder cancer. Cxbladderdetect is now being commercialised in the United States, New Zealand, Australia, and soon in Spain. The second product in the program, Cxbladdertriage, is scheduled for commercial release in New Zealand later this year.

Pacific Edge was founded to use the latest developments in molecular biology to provide actionable diagnosis that can contribute to a clinically meaningful difference in cancer detection and the management of that cancer. It is the driving force of our research and product development program” David Darling says.

“Cxbladder is a prime example. It is a quick, cost effective, non-invasive and highly accurate cancer detection test that enables clinicians to detect urothelial carcinomas, including cancers of the bladder, from a small urine sample.”

Pacific Edge’s ongoing development program includes clinical and ‘User Programs’ to validate Cxbladdertriage, a new product positioned to enable physians and clinicians to segregate out patients who have presented to the clinician with blood in their urine, who do not have bladder cancer thereby saving considerable clinical work-up cost. Another of the Company’s products in late-stage development and validation is Cxbladderpredict, a product that will enable clinicians to determine the severity of bladder cancer disease and enable them to non-invasively segregate superficial tumours from invasive tumours.

The Company’s portfolio of intellectual property continues to grow and includes patents for a gastric cancer test as well as melanoma and bladder cancers.

“We are now leveraging the experience gained in launching Cxbladder to the world’s largest health care market, the USA, into other products for the USA. We are also now looking to other targeted international markets” David Darling says.

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Final Frontier: Rocket Lab And NASA Sign Commercial Space Launch Agreement

Rocket Lab has signed a Commercial Space Launch Act Agreement with the National Aeronautics and Space Administration (NASA). The agreement enables Rocket Lab to use NASA resources - including personnel, facilities and equipment - for launch and reentry efforts. More>>

ALSO:

Scoop Business: Wheeler Downplays Scope For ‘Large’ Rates Fall

Reserve Bank governor Graeme Wheeler says some market commentators are predicting further declines in interest rates that would only make sense for an economy in recession, although some easing is likely to be needed to maintain New Zealand’s economic growth. More>>

ALSO:

Ruataniwha Dam: Consent Conditions Could Mean Reduced Intensity

Legal advice sought by the Hawke’s Bay Regional Council on the Ruataniwha Dam consent conditions has confirmed that farmers who sign up to take water from the dam could be required to reduce the intensity of their farming operation to meet the catchment’s strict nitrogen limit. More>>

Health And Safety: Bill Now Sees Rules Relaxed For Small Businesses

Health and safety law reform sparked by the Pike River coalmine disaster has been reported back from the industrial relations select committee with weakened requirements on small businesses to appoint health and safety representatives and committees. More>>

ALSO:

Bearing Fruit: Annual Fruit Exports Hit $2 Billion For First Time

The value of fruit exported rose 20 percent (up $330 million) for the June 2015 year when compared with the year ended June 2014. Both higher prices and a greater quantity of exports (up 9.0 percent) contributed to the overall rise. More>>

ALSO:

Get More From Scoop

 
 
 
 
 
 
 
 
 
Business
Search Scoop  
 
 
Powered by Vodafone
NZ independent news